Edition:
United States

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

78.34USD
4:00pm EDT
Change (% chg)

$-0.14 (-0.18%)
Prev Close
$78.48
Open
$78.78
Day's High
$78.87
Day's Low
$78.17
Volume
1,751,259
Avg. Vol
1,390,288
52-wk High
$89.71
52-wk Low
$69.35

Latest Key Developments (Source: Significant Developments)

Medtronic Endurant II/IIs stent graft system receives FDA approval to treat short neck anatomies
Monday, 9 Oct 2017 08:00am EDT 

Oct 9 (Reuters) - Medtronic Plc :Medtronic Endurant II/IIs stent graft system receives FDA approval to treat short neck anatomies when used with Heli-FX EndoAnchor system.Medtronic - ‍expanded indication enables Endurant II/IIs stent graft to be used in conjunction with Heli-FX EndoAnchor system.  Full Article

J&J diabetes care company Animas to close operations and exit insulin pump market
Thursday, 5 Oct 2017 07:00am EDT 

Oct 5 (Reuters) - Johnson & Johnson : :‍Johnson & Johnson Diabetes Care Companies - Animas corp intends to discontinue manufacturing, sale of animas vibe and onetouch ping insulin pumps.‍Johnson & Johnson Diabetes Care Companies - Animas corp also intends to close operations and exit insulin pump business​.‍Johnson & Johnson Diabetes Care Companies - Animas selected Medtronic as partner to facilitate transition for patients, caregivers, healthcare providers​.‍Johnson & Johnson Diabetes Care Companies - patients using an Animas insulin pump will be offered option to transfer to a Medtronic pump​.‍Johnson & Johnson Diabetes Care Companies - Johnson & Johnson is continuing to evaluate potential strategic options for Lifescan Inc​.‍Johnson & Johnson Diabetes Care Companies - for patients, healthcare providers outside of U.S., Canada Animas to continue to sell pumps, operate as usual​.  Full Article

Medtronic receives U.S. FDA approval for its HeartWare HVAD System for destination therapy​
Wednesday, 27 Sep 2017 04:05pm EDT 

Sept 27 (Reuters) - Medtronic Plc :Medtronic HeartWare(TM) HVAD(TM) system approved for destination therapy.Medtronic Plc - ‍Has received U.S. Food and Drug Administration approval for its HeartWare HVAD System​.  Full Article

Medtronic announces FDA approval, U.S. launch of spinal cord stimulator
Monday, 18 Sep 2017 09:00am EDT 

Sept 18 (Reuters) - Medtronic Plc :Medtronic announces FDA approval and U.S. launch of next generation spinal cord stimulator for chronic pain management.  Full Article

New five-year gender subset data from the Medtronic engage registry presented in viva late breaking trials
Wednesday, 13 Sep 2017 01:49pm EDT 

Sept 13 (Reuters) - Medtronic Plc :New five-year gender subset data from the medtronic engage registry presented in viva late breaking trials.Says ‍endurant ii aaa stent graft system continues to demonstrate "long-term durability and consistent" outcomes in among both male, female patients​.  Full Article

Medtronic plc ‍announces global launch of StealthStation ENT​
Tuesday, 12 Sep 2017 08:00am EDT 

Sept 12 (Reuters) - Medtronic Plc ::Medtronic Plc - ‍announced global launch of StealthStation ENT​.  Full Article

Medtronic announces voluntary recall of diabetes infusion sets
Monday, 11 Sep 2017 06:45am EDT 

Sept 11 (Reuters) - Medtronic Plc ::Medtronic announces voluntary recall of diabetes infusion sets.Medtronic-‍determined a component, vent membrane, in recalled infusion sets may be susceptible to being blocked by fluid during process of priming/fill-tubing​.Medtronic PLC - ‍recall is related to a certain discontinued component in infusion sets and does not include insulin pumps or glucose sensors​.Medtronic - started to inform patients worldwide of voluntary recall of specific lots of infusion sets used with all models of medtronic insulin pumps​.Medtronic - infusion sets available since April 2017 include design update of vent membrane which co believes reduces risk of insulin over-delivery.Medtronic plc - ‍voluntary recall of infusion sets is not expected to impact diabetes group revenue growth in q2 or full fiscal year​.Medtronic plc - ‍ majority of cost due to recall of infusion sets is expected to be incurred in q2.Medtronic plc - cost of recall is not expected to impact earnings per share guidance in q2 or full fiscal year.  Full Article

Medtronic announces Japanese regulatory approval for IN.PACT Admiral drug-coated balloon
Friday, 8 Sep 2017 07:00am EDT 

Sept 8 (Reuters) - Medtronic Plc :Medtronic announces japanese regulatory approval for the IN.PACT Admiral drug-coated balloon.Medtronic Plc - ‍received approval from japanese ministry of health, labour and welfare for treatment of peripheral artery disease in upper leg​.Medtronic - ‍before co can begin commercialization, it must partner with Japanese MHLW to gain reimbursement to ensure broader access to the therapy​.  Full Article

Medtronic launches long term clinical study program of infuse bone graft in 2 common spine procedures PLF, TLIF
Tuesday, 5 Sep 2017 09:00am EDT 

Sept 5 (Reuters) - Medtronic Plc ::Medtronic launches long term clinical study program of infuse bone graft in two common spine procedures: PLF and TLIF.Medtronic Plc - PLF pilot dosing study, which will include approximately 125 patients, will be followed by a TLIF pilot dosing study in 2018.  Full Article

Medtronic Q1 non-gaap earnings per share $1.12
Tuesday, 22 Aug 2017 06:45am EDT 

Aug 22 (Reuters) - Medtronic Plc ::Reg-Medtronic reports first quarter financial results.Q1 non-gaap earnings per share $1.12.Q1 gaap earnings per share $0.74.Q1 earnings per share view $1.08 -- Thomson Reuters I/B/E/S.Medtronic Plc - ‍rtg worldwide q1 revenue of $1.809 billion increased 2 percent on both a reported and constant currency basis​.Qtrly ‍revenue of $7.390 billion grew 3 pct as reported; 4 pct at constant currency​.Medtronic - ‍spine Q1 revenue of $649 million increased 1 percent on both a reported and constant currency basis​.Medtronic - ‍in fiscal year 2018, co expects diluted non-gaap eps growth to be in range of 9 to 10 percent on a comparable, constant currency basis​.Medtronic - ‍company reiterates full year revenue and eps guidance​.Medtronic - ‍CVG Worldwide q1 revenue of $2.646 billion increased 5 percent, or 6 percent on a constant currency basis​.Fy2018 earnings per share view $4.80, revenue view $29.55 billion -- Thomson Reuters I/B/E/S.Medtronic - ‍"expect to see increasing momentum coming from several new product launches over balance of fiscal year​".Fy2018 revenue view $29.55 billion -- Thomson Reuters I/B/E/S.Medtronic -‍ 2018 non-gaap eps would be affected by about negative $0.03 to positive $0.01, including about $0.00 to positive $0.02 impact in q2.Q1 revenue view $7.45 billion -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Medtronic care and American Well announce strategic partnership to integrate Telehealth capabilities

* Medtronic Care Management Services and American Well announce strategic partnership to integrate Telehealth capabilities Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)